Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Actas Espanolas De Psiquiatria|December 28, 1999
[Differential study of the complete and subclinical presentations of bulimia nervosa]F J Vaz Leal, E M Peñas LledóEating and Weight Disorders : EWD|January 30, 2008
Anterior cingulate activity in bulimia nervosa: a fMRI case studyE M Peñas-Lledó, K L Loeb, L Martin, et al.Actas Espanolas De Psiquiatria|October 17, 2001
[Prevalence of polydipsia and water intoxication in psychiatric inpatients]A Llerena, A De la Rubia Martínez, E M Peñas-LledóCurrent Drug Targets|December 16, 2006
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugsP Dorado, R Berecz, E M Peñas-Lledó, et al.The Pharmacogenomics Journal|May 30, 2012
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphismsP Dorado, E López-Torres, E M Peñas-Lledó, et al.The Pharmacogenomics Journal|February 28, 2007
Low frequency of CYP2D6 poor metabolizers among schizophrenia patientsA Llerena, P Dorado, E M Peñas-Lledó, et al.The Pharmacogenomics Journal|April 13, 2016
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from ArgentinaG Moya, P Dorado, V Ferreiro, et al.Fundamental & Clinical Pharmacology|July 20, 2007
Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 alleleP Dorado, E M Peñas-Lledó, A P González, et al.The Pharmacogenomics Journal|October 30, 2003
CYP2C9 gene and susceptibility to major depressive disorderA LLerena, R Berecz, P Dorado, et al.The Pharmacogenomics Journal|June 9, 2016
High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studiesM E G Naranjo, F de Andrés, A Delgado, et al.Pageof 2